Oncology Drugs

A new, highly selective oral drug for the most common form of dwarfism has been cleared for U.S. trials, offering hope for a more convenient treatment.

After a successful shift to a royalty model, the firm reports stronger financials and confirms it is weighing a merger or acquisition.

NASDAQ-listed Bio Green Med Solution abandons its biopharma roots for fire safety, slashing losses but facing new questions about its long-term survival.

Phase 2 data for HRS/BHB-1893 show rapid efficacy and a simplified regimen, signaling a potential new era for treating hypertrophic cardiomyopathy.

With a fortified balance sheet and promising clinical data, Monopar Therapeutics is advancing its lead drug, ALXN1840, toward a pivotal NDA filing.

New data shows Dizal's ZEGFROVY achieved an 81.3% response rate in a lung cancer subgroup with limited options, signaling a potential new first-line standard.

Agenus prepares a crucial update on its BOT+BAL immunotherapy, a potential breakthrough for cancers resistant to current treatments. What will they reveal?

Crinetics Pharmaceuticals aims to disrupt Brazil's acromegaly treatment with Palsonify, a once-daily pill challenging the standard of monthly injections.

With critical data due in 2026 and a leaner financial strategy, Zentalis is advancing its targeted therapy for a hard-to-treat ovarian cancer.

Early trial data for tazbentetol shows promise in treating schizophrenia by rebuilding synapses, a potential paradigm shift in psychiatric medicine.

Weave Bio forms a star-studded advisory board with leaders from Gilead and Takeda to navigate the high-stakes world of AI in drug development.

SciTech's ST-001 overcomes a decades-old barrier for fenretinide, showing promising results for Cutaneous T-Cell Lymphoma patients in early trials.

Maze Therapeutics posts positive Phase 2 data for its genetic kidney disease drug, but a sharp stock drop reveals investor concerns in a competitive race.

RA Capital's major investment extends Karyopharm's runway, but future funding is now directly tied to the outcome of its pivotal endometrial cancer trial.

A new Phase 2 trial is testing an inhaled version of a key IPF drug, aiming to reduce severe side effects and transform treatment for the fatal lung disease.

Following a record year, Knight Therapeutics is doubling its share repurchase plan. We analyze the strategy, financials, and what it means for investors.

With key trial enrollment complete, Pyxis Oncology refines its cancer drug MICVO for safety and prepares for pivotal data under a new, seasoned CEO.

UK biotech Amphista to showcase its innovative Targeted Glue™ platform at AACR, revealing new data for AML, lung cancer, and mesothelioma therapies.

A novel drug designed to eliminate stubborn cancer proteins enters human trials, offering a new strategy for ALK+ lung cancer patients facing resistance.

A novel blood test from C2N Diagnostics, used in a major Alzheimer's trial, shows promise in predicting disease progression, heralding a new era of precision medicine.